The Therapeutic Use of 2,3-Dimercaptopropane-1-Sulfonate in Two Cases of Inorganic Mercury Poisoning

James R Campbell, T. W. Clarkson, M. D. Omar

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Two patients had heavy metal intoxication resulting from industrial exposure to mercury vapors. One patient remained asymptomatic despite high urinary mercury levels. The second presented with a documented toxic reaction, including abnormal electromyograms and hematuria. Treatment was begun with 2,3-dimercaptopropane-1-sulfonate, an investigational drug used under Food and Drug Administration guidelines (IND 19 276). Use in both patients resulted in a dramatic change in excretion half-life of the mercury, from 33.1 days before treatment to 11.2 days during therapy. No significant toxic effects related to drug therapy were observed. Clearing of hematuria and reversal of electromyographic abnormalities were prompt in the symptomatic patient. Therapy with 2,3-dimercaptopropane-1-sulfonate was effective in these two patients.

Original languageEnglish (US)
Pages (from-to)3127-3130
Number of pages4
JournalJAMA: The Journal of the American Medical Association
Volume256
Issue number22
DOIs
StatePublished - Dec 12 1986

Fingerprint

Nervous System Mercury Poisoning
Therapeutic Uses
Mercury
Poisons
Hematuria
Investigational Drugs
Electromyography
United States Food and Drug Administration
Therapeutics
Heavy Metals
Half-Life
Guidelines
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The Therapeutic Use of 2,3-Dimercaptopropane-1-Sulfonate in Two Cases of Inorganic Mercury Poisoning. / Campbell, James R; Clarkson, T. W.; Omar, M. D.

In: JAMA: The Journal of the American Medical Association, Vol. 256, No. 22, 12.12.1986, p. 3127-3130.

Research output: Contribution to journalArticle

@article{c23c7141b3b740da97dcabaf2771b82d,
title = "The Therapeutic Use of 2,3-Dimercaptopropane-1-Sulfonate in Two Cases of Inorganic Mercury Poisoning",
abstract = "Two patients had heavy metal intoxication resulting from industrial exposure to mercury vapors. One patient remained asymptomatic despite high urinary mercury levels. The second presented with a documented toxic reaction, including abnormal electromyograms and hematuria. Treatment was begun with 2,3-dimercaptopropane-1-sulfonate, an investigational drug used under Food and Drug Administration guidelines (IND 19 276). Use in both patients resulted in a dramatic change in excretion half-life of the mercury, from 33.1 days before treatment to 11.2 days during therapy. No significant toxic effects related to drug therapy were observed. Clearing of hematuria and reversal of electromyographic abnormalities were prompt in the symptomatic patient. Therapy with 2,3-dimercaptopropane-1-sulfonate was effective in these two patients.",
author = "Campbell, {James R} and Clarkson, {T. W.} and Omar, {M. D.}",
year = "1986",
month = "12",
day = "12",
doi = "10.1001/jama.1986.03380220093029",
language = "English (US)",
volume = "256",
pages = "3127--3130",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "22",

}

TY - JOUR

T1 - The Therapeutic Use of 2,3-Dimercaptopropane-1-Sulfonate in Two Cases of Inorganic Mercury Poisoning

AU - Campbell, James R

AU - Clarkson, T. W.

AU - Omar, M. D.

PY - 1986/12/12

Y1 - 1986/12/12

N2 - Two patients had heavy metal intoxication resulting from industrial exposure to mercury vapors. One patient remained asymptomatic despite high urinary mercury levels. The second presented with a documented toxic reaction, including abnormal electromyograms and hematuria. Treatment was begun with 2,3-dimercaptopropane-1-sulfonate, an investigational drug used under Food and Drug Administration guidelines (IND 19 276). Use in both patients resulted in a dramatic change in excretion half-life of the mercury, from 33.1 days before treatment to 11.2 days during therapy. No significant toxic effects related to drug therapy were observed. Clearing of hematuria and reversal of electromyographic abnormalities were prompt in the symptomatic patient. Therapy with 2,3-dimercaptopropane-1-sulfonate was effective in these two patients.

AB - Two patients had heavy metal intoxication resulting from industrial exposure to mercury vapors. One patient remained asymptomatic despite high urinary mercury levels. The second presented with a documented toxic reaction, including abnormal electromyograms and hematuria. Treatment was begun with 2,3-dimercaptopropane-1-sulfonate, an investigational drug used under Food and Drug Administration guidelines (IND 19 276). Use in both patients resulted in a dramatic change in excretion half-life of the mercury, from 33.1 days before treatment to 11.2 days during therapy. No significant toxic effects related to drug therapy were observed. Clearing of hematuria and reversal of electromyographic abnormalities were prompt in the symptomatic patient. Therapy with 2,3-dimercaptopropane-1-sulfonate was effective in these two patients.

UR - http://www.scopus.com/inward/record.url?scp=0022870506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022870506&partnerID=8YFLogxK

U2 - 10.1001/jama.1986.03380220093029

DO - 10.1001/jama.1986.03380220093029

M3 - Article

VL - 256

SP - 3127

EP - 3130

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 22

ER -